Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-RevCAR01-T-CD123 in Relapsed/Refractory CD123+ AML
NCT05949125Phase 1Recruiting
- Sponsor
- AvenCell Therapeutics
- Start
- Jan 2024
- Primary completion
- May 2027
- Modality
- Gene Editing, Antibody Conjugates, scFv Fragments
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AVC-201 and Rev CD123-5B9 in acute myeloid leukemia (AML), sponsored by AvenCell Therapeutics. Primary endpoint: Safety and tolerability at 28 days. Started Jan 2024; status: recruiting.
02
Drugs
AVC-201Rev CD123-5B9
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05949125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949125.